Jeffrey B. Landau is Chief Business Officer at CytomX Therapeutics, Inc. (CTMX). They have made 6 open-market trades across 1 company since 2022, most recently 2024-08-20.
CIK 0001918615
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTMX | 119,056 | $280K |
Shares reported on the most recent Form 4, priced at the 2024-08-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTMX | SELL | 2024-08-20 | 2024-08-22 | $1.23 | $5K | +5.0% | -3.4% | -26.9% |
| CTMX | SELL | 2024-03-19 | 2024-03-21 | $2.09 | $14K | -2.7% | -24.4% | -42.1% |
| CTMX | SELL | 2023-12-20 | 2023-12-22 | $1.38 | $6K | +3.4% | +11.6% | +53.4% |
| CTMX | SELL | 2023-09-22 | 2023-09-22 | $1.30 | $5K | -3.2% | +1.6% | +11.9% |
| CTMX | SELL | 2023-03-16 | 2023-03-20 | $1.98 | $3K | -20.0% | -8.1% | -17.3% |
| CTMX | SELL | 2022-07-20 | 2022-07-21 | $1.42 | $6K | +5.5% | +6.2% | -8.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.